Latest Conference Articles

Dr. Edith Perez on T-DM1 and the MARIANNE Trial

Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.

No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer

PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.

Dr. Brufsky Discusses the tnAcity Trial in TNBC

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Quizartinib Active in AML at Lower Doses

Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.

Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors

A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.

Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

Dr. Goy on CAR-Modified T Cells in Lymphoma

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

NeoALTTO Analysis Finds Significant Link Between pCR and Survival

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

Dr. Arteaga Discusses the CALGB 40603 Trial

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

Dr. Kent Osborne Discusses the PRIME 2 Trial

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

Benefits of Screening Mammography Not So Inconsistent, After All

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Dr. Shah on Novel Therapies for Multiple Myeloma

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Dr. Jennifer Litton on the Phase III BETH Trial

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

Dr. Loi on the Association Between TILs and Trastuzumab

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

Latest Data Further Support Ibrutinib's Efficacy in CLL

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Dr. Furman on Avoiding Chemotherapy With Idelalisib

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

New Drug Class Shows Activity in Refractory Multiple Myeloma

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

Ibrutinib Induces Rapid, Durable Responses in Waldenström's Macroglobulinemia

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory Waldenström's macroglobulinemia, and the responses to ibrutinib were durable.

IPI-145 Has Activity in Relapsed/Refractory CLL

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.